Skip to main content
. 2017 May 3;292(24):10142–10152. doi: 10.1074/jbc.M117.788778

Figure 1.

Figure 1.

HMGCS1 knockdown selectively decreases cell proliferation potential in BRAFV600E-expressing melanoma cells. A and B, distinct human melanoma (A) or colon cancer (B) cells with HMGCS1 knockdown were tested for cell proliferation rates by daily cell counting. Immunoblotting results show HMGCS1 knockdown efficiency in corresponding cells. p values were obtained by two-tailed Student's t test. Error bars indicate ± S.D.; n = 3 each. C, immunoblotting shows HMGCS1 protein level in diverse human melanoma cells expressing BRAFV600D/E (A2058, A375, SK-MEL-5, WM-266-4) or BRAF WT (PMWK, HMCB, SK-MEL-2). D, results of quantitative PCR show HMGCS1 gene expression in human primary melanoma tissue samples expressing BRAFV600E compared with samples expressing BRAF WT. E, TCGA provisional melanoma dataset analysis shows HMGCS1 expression (mRNA level) in diverse clinical samples harvesting V600E, V600K, V600R, K601E or other mutations compared with BRAF WT. The statistic result was analyzed by population-based assessment Z scores (S.D. scores). n means sample size of each subgroup.